Cargando…

Exploratory Evaluation of EGFR-Targeted Anti-Tumor Drugs for Lung Cancer Based on Lung-on-a-Chip

In this study, we used three-dimensional (3D) printing to prepare a template of a microfluidic chip from which a polydimethylsiloxane (PDMS)lung chip was successfully constructed. The upper and lower channels of the chip are separated by a microporous membrane. The upper channel is seeded with lung...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tan, Jianfeng, Sun, Xindi, Zhang, Jianhua, Li, Huili, Kuang, Jun, Xu, Lulu, Gao, Xinghua, Zhou, Chengbin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405841/ https://www.ncbi.nlm.nih.gov/pubmed/36005014 http://dx.doi.org/10.3390/bios12080618

Ejemplares similares

Advanced lung organoids and lung-on-a-chip for cancer research and drug evaluation: a review
por: Zhu, Leqing, et al.
Publicado: (2023)

Biomimetic lung-on-a-chip to model virus infection and drug evaluation
por: Tan, Jianfeng, et al.
Publicado: (2023)

Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives
por: Cheng, Xinghua, et al.
Publicado: (2014)

Mechanisms of resistance to EGFR-targeted drugs: lung cancer
por: Morgillo, Floriana, et al.
Publicado: (2016)

Targeting lung cancer with clinically relevant EGFR mutations using anti-EGFR RNA aptamer
por: Thomas, Brian J., et al.
Publicado: (2023)

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
por: Wang, Jun, et al.
Publicado: (2016)

Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade
por: Umelo, Ijeoma Adaku, et al.
Publicado: (2015)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
por: Suda, Kenichi, et al.
Publicado: (2021)

EGFR phosphorylates and inhibits lung tumor suppressor GPRC5A in lung cancer
por: Lin, Xiaofeng, et al.
Publicado: (2014)

Lung-On-A-Chip Technologies for Disease Modeling and Drug Development
por: Konar, Dipasri, et al.
Publicado: (2016)

Targeting acetylcholine signaling modulates persistent drug tolerance in EGFR-mutant lung cancer and impedes tumor relapse
por: Nie, Meng, et al.
Publicado: (2022)

CHIP is a novel tumor suppressor in pancreatic cancer and inhibits tumor growth through targeting EGFR
por: Wang, Tianxiao, et al.
Publicado: (2014)

Anti-EGFR Antibody Reduces Lung Nodules by Inhibition of EGFR-Pathway in a Model of Lymphangioleiomyomatosis
por: Lesma, Elena, et al.
Publicado: (2015)

The influence of tumor heterogeneity on sensitivity of EGFR-mutant lung adenocarcinoma cells to EGFR-TKIs
por: Sun, Li, et al.
Publicado: (2019)

A Novel Technique to Detect EGFR Mutations in Lung Cancer
por: Liu, Yuanbin, et al.
Publicado: (2016)

Jinfukang inhibits clustering and invasion of circulating lung tumor cells by regulating the EGFR signaling pathway: Anti-metastatic mechanism of Jinfukang on lung cancer
por: Yang, Yun, et al.
Publicado: (2023)

EGFR-TKI Plus Anti-Angiogenic Drugs in EGFR-Mutated Non–Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials
por: Conforti, Fabio, et al.
Publicado: (2020)

Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma
por: Xiao, Gang, et al.
Publicado: (2023)

Relationship between the image characteristics of artificial intelligence and EGFR gene mutation in lung adenocarcinoma
por: Zhou, Guoping, et al.
Publicado: (2023)

The Effect of Tumor Microenvironment on Autophagy and Sensitivity to Targeted Therapy in EGFR-Mutated Lung Adenocarcinoma
por: Li, Yuan-Yuan, et al.
Publicado: (2015)

Blocking autophagy improves the anti-tumor activity of afatinib in lung adenocarcinoma with activating EGFR mutations in vitro and in vivo
por: Hu, Xiangxiang, et al.
Publicado: (2017)

Improving Plasmonic Photothermal Therapy of Lung Cancer Cells with Anti-EGFR Targeted Gold Nanorods
por: Knights, Oscar, et al.
Publicado: (2020)

EGFR Mutations and Lung Cancer
Publicado: (2005)

EGFR Signaling in Lung Fibrosis
por: Schramm, Fabian, et al.
Publicado: (2022)

Exploratory analysis of immunochemotherapy compared to chemotherapy after EGFR‐TKI in non–small cell lung cancer patients with EGFR mutation: A multicenter retrospective study
por: Hata, Tae, et al.
Publicado: (2023)

Fighting COVID-19 With Lung-Chips
Publicado: (2021)

Personalized prediction of EGFR mutation-induced drug resistance in lung cancer
por: Wang, Debby D., et al.
Publicado: (2013)

Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma
por: Sun, Ruizhu, et al.
Publicado: (2022)

Outcomes of salvage lung resections in advanced EGFR ‐mutant lung adenocarcinomas under EGFR TKIs
por: Chen, Ying‐Yuan, et al.
Publicado: (2021)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

Early responses of EGFR circulating tumor DNA to EGFR tyrosine kinase inhibitors in lung cancer treatment
por: Imamura, Fumio, et al.
Publicado: (2016)

Small-cell lung cancer transformation from EGFR-mutant adenocarcinoma after EGFR-TKIs resistance: A case report
por: Jiang, Yiqian, et al.
Publicado: (2021)

EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2019)

Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma
por: Budczies, Jan, et al.
Publicado: (2021)

The High Proportion of Discordant EGFR Mutations among Multiple Lung Tumors
por: Lee, Hyunwoo, et al.
Publicado: (2022)

Anti-EGFR antibody conjugated silica nanoparticles as probes for lung cancer detection
por: Wan, Jun, et al.
Publicado: (2017)

Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR
por: Narayanan, Dilip, et al.
Publicado: (2017)

EGFR targeted therapy in lung cancer; an evolving story
por: Bartholomew, C., et al.
Publicado: (2017)

EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR
por: Jo, Ukhyun, et al.
Publicado: (2014)

Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond
por: Delaney, Christopher, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_pta4si05stdk7j2pfansv91kv6